Login / Signup

From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America.

Carlos Alberto VaccaroFrancisco López-KostnerDella Valle AdrianaEdenir Inez PalmeroBenedito Mauro RossiMarina AnteloAngela SolanoDirce Maria CarraroNora Manoukian ForonesMabel BohorquezLeonardo Saúl Lino-SilvaJose BulejeFlorencia SpirandelliKiyoko Abe-SandesIvana NascimentoYasser SullcahuamanCarlos SarrocaMaria Laura GonzalezAlberto Ignacio HerrandoKarin AlvarezFlorencia NeffaHenrique Camposreis GalvãoPatricia EsperonMariano GolubickiDaniel CisternaFlorencia C CardosoGiovana Tardin TorrezanSamuel Aguiar JuniorCélia Aparecida Marques PimentaMaria Nirvana da Cruz FormigaErika SantosCaroline U SáEdite P OliveiraRicardo FujitaEnrique SpirandelliGeiner JimenezRodrigo Santa Cruz GuindaliniRenata Gondim Meira Velame de AzevedoLarissa Souza Mario BuenoSonia Tereza Dos Santos NogueiraMariela Torres LoarteJorge PadronMaria Del Carmen Castro-MujicaJulio Sanchez Del MonteCarmelo CaballeroCarlos Mario Muñeton PeñaJoseph PintoClaudia Barletta-CarrilloGutiérrez Angulo MelvaTamara PiñeroPaola Montenegro BeltranPatricia Ashton-ProllaYenni RodriguezRichard QuispeNorma Teresa RossiClaudia MartinSergio ChialinaPablo German KalfayanJuan Carlos Bazo-AlvarezAlcides Recalde CañeteConstantino Dominguez-BarreraLina NuñezSabrina Daniela Da SilvaYesilda BalavarcaPatrik WernhoffJohn-Paul PlazzerPål MøllerEivind HovigMev Dominguez-Valentinnull null
Published in: International journal of cancer (2018)
Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and Argentina. We provide a global snapshot of the CRC patterns, how screening is performed, and compared/contrasted to the genetic profile of Lynch syndrome (LS) in the region. From the literature, we find that only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC, and also with a low adherence. We describe a genetic profile of LS, including a total of 2,685 suspected families, where confirmed LS ranged from 8% in Uruguay and Argentina to 60% in Peru. Among confirmed LS, path_MLH1 variants were most commonly identified in Peru (82%), Mexico (80%), Chile (60%), and path_MSH2/EPCAM variants were most frequently identified in Colombia (80%) and Argentina (47%). Path_MSH6 and path_PMS2 variants were less common, but they showed important presence in Brazil (15%) and Chile (10%), respectively. Important differences exist at identifying LS families in Latin American countries, where the spectrum of path_MLH1 and path_MSH2 variants are those most frequently identified. Our findings have an impact on the evaluation of the patients and their relatives at risk for LS, derived from the gene affected. Although the awareness of hereditary cancer and genetic testing has improved in the last decade, it is remains deficient, with 39%-80% of the families not being identified for LS among those who actually met both the clinical criteria for LS and showed MMR deficiency.
Keyphrases